Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

407
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
407
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

440
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
440
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

525
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
525
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

532
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
532
Drug Therapy01:28

Drug Therapy

116
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
116
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

440
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
440

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attitudes of Mental Healthcare Professionals Towards the Use of Psychedelics in the Treatment of Substance Use Disorders: A Systematic Review.

Journal of psychoactive drugs·2026
Same author

Psychoeducation for Relatives of Young Adults with First-Episode Psychosis: A Qualitative Exploration of Needs and Experiences.

Nursing reports (Pavia, Italy)·2025
Same author

Addressing Tobacco Use Disorder in Individuals With Mental Health Disorders: The Critical Role of Nurses.

Journal of advanced nursing·2024
Same author

Psychedelics as a potential treatment for tobacco use disorder: a systematic review.

Discover mental health·2024
Same author

Self-stigma, religiosity, and perceived social support in people with recent-onset psychosis in the Islamic Republic of Iran: Associations with symptom severity and psychosocial functioning.

The International journal of social psychiatry·2024
Same author

Financial dissatisfaction in people with psychotic disorders - A short report on its prevalence and correlates in a large naturalistic psychosis cohort.

Journal of psychiatric research·2024

Related Experiment Video

Updated: Oct 11, 2025

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

8.7K

[An antipsychotic without dopamine receptor blockade?]

S K Spoelstra, R Bruggeman, H Knegtering

    Tijdschrift Voor Psychiatrie
    |December 1, 2021
    PubMed
    Summary

    SEP-363856, a novel antipsychotic targeting trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1a receptors, shows promise for treating psychosis. This new class of medication demonstrated efficacy and good tolerability in a phase 2 clinical trial.

    Area of Science:

    • Psychiatry and Neuroscience
    • Pharmacology
    • Clinical Trials

    Background:

    • Current antipsychotic treatments are suboptimal, necessitating novel agents with distinct mechanisms of action.
    • SEP-363856 is a novel compound investigated for its antipsychotic potential.
    • It acts as a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1a receptor agonist.

    Purpose of the Study:

    • To review the development rationale and pharmacology of TAAR1/5-HT1a agonists.
    • To present the clinical efficacy and tolerability of SEP-363856.

    Main Methods:

    • A narrative literature review was conducted.
    • Databases searched include PubMed, Embase, and PsychINFO.
    • The review focused on publications related to SEP-363856 and TAAR1/5-HT1a agonism.

    More Related Videos

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.4K
    Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
    05:52

    Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

    Published on: November 21, 2013

    15.1K

    Related Experiment Videos

    Last Updated: Oct 11, 2025

    Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
    07:25

    Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

    Published on: March 27, 2018

    8.7K
    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.4K
    Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
    05:52

    Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

    Published on: November 21, 2013

    15.1K

    Main Results:

    • A phase 2 clinical trial of SEP-363856 was identified and analyzed.
    • SEP-363856 demonstrated efficacy in reducing both positive and negative symptoms of psychosis.
    • The drug was well-tolerated, with minimal motor side effects, prolactin increase, or metabolic issues; somnolence and nausea were reported.

    Conclusions:

    • SEP-363856's antipsychotic activity is linked to TAAR1 and 5-HT1a agonism, not D2 antagonism.
    • TAAR1 and 5-HT1a agonists represent a potential new treatment avenue for psychosis.
    • Further development of SEP-363856 could lead to an antipsychotic with improved effectiveness and tolerability.